Astellas Pharma (ALPMY) Projected to Release Quarterly Earnings on Wednesday

Astellas Pharma (OTCMKTS:ALPMY) is expected to be announcing its results after the market closes on Wednesday, November 4th. Analysts expect Astellas Pharma to announce earnings of $0.4113 per share and revenue of $3.79 billion for the quarter.

Astellas Pharma Stock Up 0.3%

OTCMKTS:ALPMY opened at $16.21 on Tuesday. The company has a market cap of $29.33 billion, a PE ratio of 9.51 and a beta of 0.08. Astellas Pharma has a twelve month low of $10.32 and a twelve month high of $17.35. The company has a current ratio of 1.20, a quick ratio of 0.93 and a debt-to-equity ratio of 0.16. The company’s 50 day moving average is $15.01 and its two-hundred day moving average is $14.72.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.

Astellas’ portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.